About the Authors

Samia Mourah

samia.mourah@sls.aphp.fr

Affiliations Department of Pharmacology-Genetics, AP-HP, Saint-Louis Hospital, Paris, France, INSERM UMRS 976 Paris, F-75010, France

Marc G. Denis

Affiliation Department of Biochemistry, Nantes University Hospital, Nantes, France

Fabienne Escande Narducci

Affiliation Department of Molecular Biology and Biochemistry, Lille Regional University Hospital, Lille, France

Jérôme Solassol

Affiliation Department of Biology—Pathology, Montpellier University Hospital, Montpellier, France

Jean-Louis Merlin

Affiliation Department of Tumor Biology, Alexis Vautrin Center, Vandoeuvre les Nancy, France

Jean-Christophe Sabourin

Affiliation Department of Pathology—Cytopathology, Rouen University Hospital, Rouen, France

Jean-Yves Scoazec

Affiliations Laboratory of Pathology and Cytopathology, Edouard Herriot Hospital, Lyon, France, Department of Biology and Pathology, Gustave Roussy Hospital, Villejuif, France

L’Houcine Ouafik

Affiliation Department of Cancer Biology, Marseille Nord University Hospital, Marseille, France

Jean-François Emile

Affiliation Department of Pathology, Ambroise Paré Hospital, Boulogne-Billancourt, France

Remy Heller

Affiliation Department of Microbiology and Molecular Biology, Colmar hospital, Colmar, France

Claude Souvignet

Affiliation Roche, Boulogne-Billancourt, France

Loïc Bergougnoux

Affiliation Roche, Boulogne-Billancourt, France

Jean-Philippe Merlio

Affiliation Department of Tumor Biology, Bordeaux University Hospital, Bordeaux, France

Competing Interests

The authors have read the journal's policy and have the following competing interests: SM: Scientific committee board membership Paraf’in study. Consulting fees or other remuneration: Roche, Novartis, GSK. MD: Scientific committee board membership Paraf’in study. Consulting fees or other remuneration: Roche, Astra-Zeneca, Boehringer Ingelheim, Qiagen. JLM: Consulting fees or other remuneration, Roche; Other, amgen, bayer, GSK, Lilly, Merck-Serono, Novartis, Roche, Sanofi. JCS: Consulting fees or other remuneration, Roche, Boehringer Ingelmen, Merck; Research grants, Roche; Other, Amgen. JYS: Research grants, Novartis, Ipsen; Consulting fees or other remuneration, Roche. FEN, JS, LHO: none. JFE: Research grants, Roche; Consulting fees or other remuneration, Roche. RH: Research grants, Roche. LB, CS: Employee, Roche. JPM: Scientific committee board membership Paraf’in study. This does not alter the authors' adherence to PLOS ONE policies on sharing data and materials.

Author Contributions

Conceived and designed the experiments: SM MD JCS JYS JPM LHO. Performed the experiments: SM MD FEN JS JLM JCS JYS LHO JFE RH CS LB JPM. Analyzed the data: SM MD FEN JS JLM JCS JYS LHO JFE RH CS LB JPM. Contributed reagents/materials/analysis tools: SM MD FEN JS JLM JCS JYS LHO JFE RH JPM. Wrote the paper: SM MD FEN JS JLM JCS JYS LHO JFE RH CS LB JPM.